Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Human challenge study

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant

Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses

- PMLiVE

Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall

US development partner Ocugen is already planning to submit a BLA for the vaccine to the FDA

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

COVID-19 booster dose programme planned for September launch in Britain

The programme will be conducted in two stages for a range of priority groups

- PMLiVE

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

Scientists highlighted the potential of two drugs, one for rheumatoid arthritis and one for malaria

- PMLiVE

WHITE PAPER: From bench to bedside in one year – how the race for a COVID-19 vaccine will change the future of drug development

In this edition of MAGNIFI, we discuss the factors behind this acceleration in development of the COVID-19 vaccines and what this might mean for the future of pharma

IGNIFI

- PMLiVE

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

Report

Digital Health Tools - Physician Trends

Research Partnership

- PMLiVE

Moderna says its COVID-19 vaccine appears effective against Delta and other variants

Earlier this year, the company revealed early evidence that its booster jabs may be effective against ‘variants of concern’

- PMLiVE

EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

The five therapeutic candidates include a repurposed arthritis med and monoclonal antibodies

- PMLiVE

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links